Ratings Autolus Therapeutics plc

Equities

AUTL

US05280R1005

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
4 ^USD	-6.54%		-4.53%	-37.89%

Jun. 01	Transcript : Autolus Therapeutics plc - Special Call
May. 31	Autolus Therapeutics plc Presents Long-Term Follow-Up and Additional Data Analysis of Pivotal Phase 2 FELIX Study of Obecabtagene Autoleucel in an Oral Presentation at ASCO	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
AUTOLUS THERAPEUTICS PLC	-37.89%	1.06B	-
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B	B+
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B	B+
BIONTECH SE	-4.93%	24.21B	B+
ARGENX SE	+3.23%	22.78B	B
GENMAB A/S	-10.44%	17.96B	A-
WUXI APPTEC CO., LTD.	-41.74%	16.43B	A-
BEIGENE, LTD.	-13.31%	16.37B	B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B	C+
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes